Conference Day Two
November 13, 2024
8:00 am Chair’s Opening Remarks
From Depletion to Dampening: Tolerance for Immune Reconstitution After Reset
8:10 am A Dual-cell Bidirectional Agonist Antibody Approach for the Treatment of Autoimmune Disease
Synopsis
- Introducing the role of checkpoint receptors in autoimmunity
- Comparing current approaches for checkpoint agonism in autoimmunity
- Detailing Seismic’s novel approach
8:30 am Restoring Balance to the Immune System with Engineered Treg Therapies
Synopsis
- Presentation details to follow
8:50 am Building a Pipeline of Engineered CAR-Treg Cell Therapies for Transplantation & Autoimmunity
Synopsis
- CAR-Treg products for modulation of immune tolerance & tissue homeostasis
- Covering technologies to modulate CAR-Treg safety, stability, persistence, functionality
- Establishing a robust large scale GMP manufacturing process and capability to deliver clinical supply
- Early learnings from the clinic with QEL-001 in Liver Transplantation
9:10 am Morning Break & Prescheduled 1-to-1 Networking using ONE Partnering
10:50 am Immune Reconstitution – Do we Need it?
Synopsis
Discussing key questions as data emerges:
- Do we need reconstitution after cell depletion? What are the pros and cons?
- Maintenance therapy versus induction therapy – are we there yet?
- What is beyond SLE? Discussing data for efficacy and safety in RA and other autoimmune disease
Effectively Translating & Evolving Clinical or Corporate Development as the Immuno-Oncology Toolbox Pivots
11:30 am Roundtable Discussions for Scientific & Business Alignment:
Synopsis
- Join roundtables of companies across cell therapy, cell engager, complex biologics, tolerization, and engineered Tregs to discuss how different groups are approaching shared drug and corporate development hurdles to collectively revolutionize existing or open new opportunities.
TRANSLATIONAL TABLE
Developing Effective Preclinical Models
for Autoimmune Disease:
• Which models are we using, which
models work, and how translatable
are these models?
• Do we need disease models at all?
What do the regulators want to see?
• Should in silico modeling and other
non-animal model types be further
explored?
CLINICAL TABLE
Improving Clinical Endpoints &
Optimizing Trial Design:
• Discussing biomarkers of efficacy and
durability to support proof-of-concept
and measure the persistence of
immune reconstitution
• Are basket trials the way forward?
• Do we know what clinical readouts
and endpoints look like for
autoimmune disease? How can we
implement surrogate endpoints?
CORPORATE TABLE
Effectively & Efficiently Structuring
Deal Processes as a Small Immunology
Company:
• Discussing shared experiences
executing notable collaborations
• How to differentiate in the buy/sell
dynamic as the field quickly evolves
• What can creative partnerships and
deal structures look like to create
effective BD&L in 2025
12:00 pm Lunch Break & Prescheduled 1-to-1 Networking using ONE Partnering
Win or Fail, What is the Next Thing? Finding the Next Generation of Therapeutics or Targets
1:30 pm Immune Cell Reprogramming for Tolerance – What Motivates this Approach
Synopsis
- Introducing immune cell reprogramming for reconstitution
- Comparing this approach with broader immune reconstitution approaches
- Flip Therapeutic’s origin story
1:50 pm Creating the Big Picture: Using Multi-Modal Data for Future Immunology Targets
Synopsis
- Discussing the breaking wave behind known targets and therapeutics for reconstitution
- Different ways to create the big picture; how are AI-centric, experimental phenotypic, and big data approaches identifying future immunological targets
- Reviewing how future immunology target opportunities fit into the picture evolving today